Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Translational Lung Cancer ResearchOpen Access

Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSuguru MuraokaNKNobuaki KobayashiAKAyami KanekoYokohama City University

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows no improvement in overall survival for PD-L1 negative NSCLC with ICIs compared to chemotherapy.

Key Points

  • No significant difference in overall survival between PD-L1 negative NSCLC patients receiving ICIs and chemotherapy was observed.
  • Among 86 patients analyzed, the overall response rate was higher for IC group at 50%, compared to 34.4% for chemotherapy alone.
  • Retrospective analysis of advanced NSCLC patients treated between 2015 and 2022 in Japan was conducted across multiple centers.
  • Limited efficacy of ICIs in PD-L1 negative NSCLC highlights the need for further research on treatment strategies.

Cite This Study

Muraoka et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d647914adhttps://doi.org/10.21037/tlcr-2025-138
View Full Paper
Ask AI
Bookmark
Share